JP2018508188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508188A5 JP2018508188A5 JP2017536356A JP2017536356A JP2018508188A5 JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5 JP 2017536356 A JP2017536356 A JP 2017536356A JP 2017536356 A JP2017536356 A JP 2017536356A JP 2018508188 A5 JP2018508188 A5 JP 2018508188A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021038857A JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2015/050276 | 2015-01-08 | ||
| PCT/EP2015/050276 WO2015104346A1 (en) | 2014-01-09 | 2015-01-08 | Humanized or chimeric cd3 antibodies |
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500412 | 2015-07-15 | ||
| DKPA201500413 | 2015-07-15 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500416 | 2015-07-16 | ||
| DKPA201500415 | 2015-07-16 | ||
| DKPA201500415 | 2015-07-16 | ||
| PCT/EP2016/050296 WO2016110576A1 (en) | 2015-01-08 | 2016-01-08 | Bispecific antibodies against cd3 and cd20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Division JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508188A JP2018508188A (ja) | 2018-03-29 |
| JP2018508188A5 true JP2018508188A5 (OSRAM) | 2019-02-14 |
| JP6853176B2 JP6853176B2 (ja) | 2021-03-31 |
Family
ID=56355550
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536356A Active JP6853176B2 (ja) | 2015-01-08 | 2016-01-08 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021038857A Active JP7177317B2 (ja) | 2015-01-08 | 2021-03-11 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
| JP2022162493A Active JP7596342B2 (ja) | 2015-01-08 | 2022-10-07 | Ｃｄ３およびｃｄ２０に対する二重特異性抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10544220B2 (OSRAM) |
| EP (1) | EP3242682A1 (OSRAM) |
| JP (3) | JP6853176B2 (OSRAM) |
| KR (3) | KR102712786B1 (OSRAM) |
| CN (2) | CN114478792A (OSRAM) |
| AU (3) | AU2016205967B2 (OSRAM) |
| CA (1) | CA2973159A1 (OSRAM) |
| EA (1) | EA201791554A1 (OSRAM) |
| IL (3) | IL289946B2 (OSRAM) |
| MX (2) | MX391279B (OSRAM) |
| SG (1) | SG11201705496SA (OSRAM) |
| UA (1) | UA120286C2 (OSRAM) |
| WO (1) | WO2016110576A1 (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2647707T (lt) * | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| KR102357961B1 (ko) | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| CA2958479A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
| US10323094B2 (en) | 2015-06-16 | 2019-06-18 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
| WO2016204966A1 (en) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| JP6996983B2 (ja) | 2015-06-16 | 2022-02-21 | ジェネンテック， インコーポレイテッド | 抗ｃｌｌ－１抗体及び使用方法 |
| IL256562B2 (en) | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| AU2018276419A1 (en) * | 2016-06-02 | 2019-10-17 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer |
| JP7083819B2 (ja) * | 2016-09-30 | 2022-06-13 | セントレ ナショナル デ ラ レセルシュ シャンティフィク | 細胞マーカー |
| WO2018093821A1 (en) * | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
| JP7247091B2 (ja) * | 2016-12-20 | 2023-03-28 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法 |
| CN111356477B (zh) * | 2017-08-01 | 2024-08-30 | Ab工作室有限公司 | 双特异性抗体及其用途 |
| JP7290013B2 (ja) | 2017-08-04 | 2023-06-13 | ジェンマブ エー／エス | Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用 |
| EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| CN107501412A (zh) * | 2017-10-11 | 2017-12-22 | 深圳精准医疗科技有限公司 | 突变型双特异性抗体及其应用 |
| MX2020008289A (es) | 2018-02-08 | 2020-09-25 | Genentech Inc | Moleculas biespecificas de union al antigeno y metodos de uso. |
| US20210032358A1 (en) * | 2018-02-09 | 2021-02-04 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses |
| JP7377590B2 (ja) | 2018-03-14 | 2023-11-10 | ノビミューン エスアー | 抗ｃｄ３イプシロン抗体およびそれを使用する方法 |
| EP3569617A1 (en) * | 2018-05-18 | 2019-11-20 | Trion Research GmbH | Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases |
| CN110540593B (zh) * | 2018-05-29 | 2022-05-17 | 上海药明生物技术有限公司 | 新型的抗cd3/抗cd20双特异性抗体 |
| US12129298B2 (en) * | 2018-06-21 | 2024-10-29 | Daiichi Sankyo Company, Limited | Compositions including CD3 antigen binding fragments and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109836502B (zh) * | 2018-11-12 | 2021-09-07 | 浙江大学 | 一种双特异性抗体及其应用 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| KR20210142638A (ko) * | 2019-02-22 | 2021-11-25 | 우한 이지 바이오파마 씨오., 엘티디. | Cd3 항원 결합 단편 및 이의 응용 |
| EP3969907B1 (en) * | 2019-05-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Interference-suppressed pharmacokinetic immunoassay |
| CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
| AU2020328195A1 (en) | 2019-08-15 | 2022-03-03 | Genmab A/S | Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses |
| CN111100204B (zh) * | 2019-11-26 | 2022-03-11 | 山东立菲生物产业有限公司 | 靶向cd20的抗体、其制备方法和应用 |
| BR112022011357A2 (pt) | 2019-12-13 | 2022-08-23 | Genentech Inc | Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo |
| CN115768483A (zh) * | 2020-01-13 | 2023-03-07 | 西纳福克斯股份有限公司 | 抗体与免疫细胞衔接器的缀合物 |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| AU2021236906A1 (en) * | 2020-03-18 | 2022-08-18 | Genmab A/S | Antibodies binding to B7H4 |
| US20230227570A1 (en) | 2020-05-08 | 2023-07-20 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| US11976120B2 (en) | 2020-06-01 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| US10981996B1 (en) | 2020-06-01 | 2021-04-20 | Abexxa Biologics, Inc. | Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| CN116406293A (zh) | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
| BR112023004296A2 (pt) | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma de célula b grande difusa em um indivíduo humano |
| JP2023541860A (ja) * | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| BR112023004319A2 (pt) * | 2020-09-10 | 2023-04-04 | Genmab As | Método para tratar linfoma difuso de grandes células b |
| CA3190376A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| TWI888665B (zh) | 2020-11-04 | 2025-07-01 | 美商建南德克公司 | 抗cd20/抗cd3雙特異性抗體之皮下給藥 |
| US12351643B2 (en) | 2020-11-04 | 2025-07-08 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| EP4304616A4 (en) * | 2021-03-10 | 2025-02-26 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | COMPOSITIONS AND METHODS FOR REDUCING THE TOXICITY OF THERAPEUTIC T CELLS |
| JP2024512386A (ja) * | 2021-03-12 | 2024-03-19 | ジェンマブ エー／エス | 非活性化抗体バリアント |
| MX2023012408A (es) | 2021-04-30 | 2023-10-31 | Hoffmann La Roche | Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b. |
| US12291575B2 (en) | 2021-05-14 | 2025-05-06 | Genentech, Inc. | Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin |
| KR20240135663A (ko) | 2022-01-28 | 2024-09-11 | 젠맵 에이/에스 | 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체 |
| US20230303693A1 (en) | 2022-01-28 | 2023-09-28 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| WO2023201226A1 (en) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| WO2023198839A2 (en) | 2022-04-13 | 2023-10-19 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| CA3247048A1 (en) | 2022-04-13 | 2023-10-19 | Genentech Inc | PHARMACEUTICAL COMPOSITIONS OF MOSUNETUZUMAB AND METHODS OF USE |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| IL321437A (en) * | 2022-12-14 | 2025-08-01 | Evolveimmune Therapeutics Inc | Bispecific antibody fusion molecules and methods for using them |
| KR20250151441A (ko) | 2023-02-17 | 2025-10-21 | 리제너론 파마슈티칼스 인코포레이티드 | Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2024213754A1 (en) | 2023-04-13 | 2024-10-17 | Genmab A/S | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 |
| WO2024236031A1 (en) | 2023-05-15 | 2024-11-21 | Genmab A/S | Highly purified epcoritamab compositions |
| US20240409656A1 (en) | 2023-05-15 | 2024-12-12 | Genmab A/S | Methods of treating cd20 expressing b-cell cancers |
| WO2025064890A1 (en) * | 2023-09-20 | 2025-03-27 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof |
| WO2025109119A1 (en) * | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035607A2 (en) * | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2856451T3 (es) * | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
| WO2008145141A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Method for extending the half-life of exogenous or endogenous soluble molecules |
| EP2167669A2 (en) * | 2007-05-31 | 2010-03-31 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
| WO2008145137A2 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering |
| AU2009299794B2 (en) * | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| EP2519544A1 (en) | 2009-12-29 | 2012-11-07 | Emergent Product Development Seattle, LLC | Polypeptide heterodimers and uses thereof |
| CN110066339A (zh) * | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| LT2647707T (lt) * | 2010-11-30 | 2018-11-12 | Chugai Seiyaku Kabushiki Kaisha | Citotoksiškumą indukuojantis terapinis agentas |
| JP2014514314A (ja) * | 2011-04-20 | 2014-06-19 | ゲンマブ エー／エス | Ｈｅｒ２およびｃｄ３に対する二重特異性抗体 |
| ME03440B (me) | 2011-05-21 | 2020-01-20 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| PT2748201T (pt) | 2011-08-23 | 2018-02-08 | Roche Glycart Ag | Moléculas de ligação ao antigénio biespecíficas que ativam as células t |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014131711A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| RU2015140915A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| MX2016000272A (es) * | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
| KR102357961B1 (ko) * | 2013-12-17 | 2022-02-08 | 제넨테크, 인크. | 항-cd3 항체 및 이의 사용 방법 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| SI3221359T1 (sl) | 2014-11-17 | 2020-08-31 | Regeneron Pharmaceuticals, Inc. | Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20 |
| US20170349657A1 (en) | 2016-06-01 | 2017-12-07 | Xencor, Inc. | Bispecific antibodies that bind cd20 and cd3 |
| EP3668898B1 (en) * | 2017-08-14 | 2023-07-05 | MorphoSys AG | Humanized antibodies for cd3 |
| CN116406293A (zh) * | 2020-09-10 | 2023-07-07 | 健玛保 | 用于治疗滤泡性淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体 |
-
2016
- 2016-01-08 CN CN202210117824.1A patent/CN114478792A/zh active Pending
- 2016-01-08 WO PCT/EP2016/050296 patent/WO2016110576A1/en not_active Ceased
- 2016-01-08 KR KR1020247014333A patent/KR102712786B1/ko active Active
- 2016-01-08 EA EA201791554A patent/EA201791554A1/ru unknown
- 2016-01-08 UA UAA201708112A patent/UA120286C2/uk unknown
- 2016-01-08 KR KR1020247032341A patent/KR20240148942A/ko active Pending
- 2016-01-08 CA CA2973159A patent/CA2973159A1/en active Pending
- 2016-01-08 EP EP16700133.8A patent/EP3242682A1/en active Pending
- 2016-01-08 KR KR1020177021738A patent/KR102663073B1/ko active Active
- 2016-01-08 AU AU2016205967A patent/AU2016205967B2/en active Active
- 2016-01-08 IL IL289946A patent/IL289946B2/en unknown
- 2016-01-08 CN CN201680014755.4A patent/CN107660214B/zh active Active
- 2016-01-08 MX MX2017008875A patent/MX391279B/es unknown
- 2016-01-08 JP JP2017536356A patent/JP6853176B2/ja active Active
- 2016-01-08 US US15/541,594 patent/US10544220B2/en active Active
- 2016-01-08 SG SG11201705496SA patent/SG11201705496SA/en unknown
- 2016-01-08 IL IL318350A patent/IL318350A/en unknown
-
2017
- 2017-06-25 IL IL253166A patent/IL253166B/en unknown
- 2017-07-04 MX MX2022004082A patent/MX2022004082A/es unknown
-
2019
- 2019-12-04 US US16/702,996 patent/US20200199231A1/en active Pending
-
2021
- 2021-03-11 JP JP2021038857A patent/JP7177317B2/ja active Active
-
2022
- 2022-02-10 AU AU2022200871A patent/AU2022200871B2/en active Active
- 2022-10-07 JP JP2022162493A patent/JP7596342B2/ja active Active
-
2025
- 2025-08-07 AU AU2025213616A patent/AU2025213616A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508188A5 (OSRAM) | ||
| US10899842B2 (en) | 4-1BB binding proteins and uses thereof | |
| TWI508745B (zh) | ＴＮＦ－α結合蛋白 | |
| US8877194B2 (en) | TNF-α binding proteins | |
| CN102906113B (zh) | 治疗性dll4结合蛋白 | |
| JP2023002615A5 (OSRAM) | ||
| JP2016529882A5 (OSRAM) | ||
| JP2018183173A5 (OSRAM) | ||
| EP3634998B1 (en) | Anti-cd3 epsilon antibodies | |
| EP2928919A2 (en) | Blood-brain barrier (bbb) penetrating dual specific binding proteins | |
| CN102655880A (zh) | Il-1结合蛋白 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| KR20110040886A (ko) | 프로스타글란딘 ｅ2 결합 단백질 및 이의 용도 | |
| KR20110110349A (ko) | Ｉｌ-1 결합 단백질 | |
| EP2970457A2 (en) | Dual specific binding proteins directed against tnf | |
| TW201307388A (zh) | Ｉｌ－１結合蛋白 | |
| WO2013157105A1 (ja) | ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用 | |
| JP2017507131A5 (OSRAM) | ||
| RU2005121669A (ru) | Анти-nogo антитела ("11с7") и их фармацевтическое использование | |
| JPWO2022111425A5 (OSRAM) | ||
| AU2024255174A1 (en) | Methods of treating lymphoma with bispecific antibodies against cd3 and cd20 | |
| WO2022238459A1 (en) | New humanized anti-vegfc antibodies and uses thereof | |
| JPWO2023138551A5 (OSRAM) | ||
| CN120548328A (zh) | 混杂的cd3结合分子 |